The Big Three PBMs’ 2024 Formulary Exclusions: Biosimilar Humira Battles, CVS Health’s Weird Strategy, and the Insulin Shakeup
Drug Channels
JANUARY 9, 2024
For 2024, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)—have again each excluded 600 or more drugs from their standard formularies. CVS Health will lean into the craziness with a widely misunderstood—but unambiguously anti-biosimilar—Humira strategy.
Let's personalize your content